The spread of COVID-19 has presented the global healthcare and life sciences sectors with unprecedented challenges. At the same time, it has underscored how quickly the industry can pivot to boost capacity in critical areas and support significant rapid changes in demand for technology and devices around the world.
As well as the immediate pressures on governments and healthcare services, COVID-19 has also unearthed important questions for the future of medical devices and technology. For instance, in years to come, which medical devices will be regarded as ‘critical’? How will this affect the supply chains of the companies producing these devices? What government regulations and requirements will exist for safeguarding domestic populations?
The opportunities and challenges that we discuss in this paper are designed to provide a rough guide to success in the medical technology space. At Alvarez & Marsal, we are leveraging our specialisms in operational transformation, transaction advisory and supply chain to guide leading enterprises through difficult times. We look forward to observing and contributing as the medical technology sector continues to develop.
Click here to read the article.
Alvarez & Marsal advises the promoters of Asian Institute of Medical Sciences on securing private credit from 360 ONE Asset Management
June 19, 2026
Alvarez & Marsal (A&M) acted as the exclusive financial advisor to the promoters of Blue Sapphire Healthcares Private Limited, the operator of Asian Institute of Medical Sciences (AIMS), on securing private credit from 360 ONE Asset Management. The capital will enable the promoters to consolidate their shareholding in the business.
Alvarez & Marsal builds restructuring and turnaround expertise in Italy with two senior hires
June 19, 2026
Sector experts Claudia Lotti and Francesco Leone join as Managing Directors to co-lead A&M’s Financial and Operational Restructuring team in Milan
Activist pressure starts with underperformance
June 18, 2026
Shareholder activism is accelerating, and the root cause is consistent: sustained operational underperformance relative to peers. In a feature for CFO.com, A&M Managing Director Ron Orsini outlines a more disciplined path: close performance gaps early, build a credible value creation plan, and retain control of your strategy before activists define it for you.
Alvarez and Marsal advises on landmark $9bn UK Restructuring Plans for New Fortress Energy
June 18, 2026
Alvarez and Marsal acted as financial advisor to NFE on its landmark UK Restructuring Plan, following sanction by the High Court of England and Wales of two inter-conditional Restructuring Plans under Part 26A of the Companies Act.
